Get the Stockscreener App
1.33
8.13%
0.10
Pre-market:
1.31
-0.02
-1.50%
Inovio Pharmaceuticals Inc stock is traded at $1.33, with a volume of 3.33M.
It is up +8.13% in the last 24 hours and up +17.70% over the past month.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
See More
Previous Close:
$1.23
Open:
$1.25
24h Volume:
3.33M
Relative Volume:
1.38
Market Cap:
$109.42M
Revenue:
$65,300
Net Income/Loss:
$-84.95M
P/E Ratio:
-0.688
EPS:
-1.9332
Net Cash Flow:
$-88.92M
1W Performance:
-2.21%
1M Performance:
+17.70%
6M Performance:
-24.43%
1Y Performance:
-32.83%
1-Day Range:
$1.22
$1.34
1-Week Range:
$1.20
$1.445
52-Week Range:
$1.03
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.33 | 101.20M | 65,300 | -84.95M | -88.92M | -1.9332 |
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.59 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.22 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.51 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.73 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial - Stocktwits
ApolloBio reports positive phase 3 results for VGX-3100 in China - Investing.com UK
Positive Phase 3 Results for Inovio (INO) Partnered VGX-3100 in China - GuruFocus
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio (NASDAQ: INO) director awarded RSUs and 41,800 options - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Inovio (NASDAQ: INO) grants RSUs and stock options to director Ann Calby Miller - Stock Titan
Equity grants to Inovio (NASDAQ: INO) director David Weiner disclosed - Stock Titan
Inovio (NASDAQ: INO) director receives RSUs and stock options grant - Stock Titan
Inovio (NASDAQ: INO) director granted 34,200 RSUs and 41,800 options - Stock Titan
INOVIO (INO) Chief Scientific Officer reports RSU vesting, tax withholding and new stock option awards - Stock Titan
Inovio (INO) CMO granted RSUs and 46,876 stock options at $1.73 - Stock Titan
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China - PR Newswire
Inovio (INO) CFO granted stock options, RSUs and reports RSU vesting - Stock Titan
Inovio (NASDAQ: INO) CEO receives new RSUs and options as shares withheld for taxes - Stock Titan
Inovio Shareholders Endorse Governance Changes and Leadership - TipRanks
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Inovio (NASDAQ: INO) overhauls board roles and wins approval on all 2026 shareholder proposals - Stock Titan
Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who L - GuruFocus
$Moderna (MRNA.US)$ $Inovio Pharmaceuticals (INO.US)$ $3M (MMM.US)$ - Moomoo
Earnings call transcript: Inovio beats Q1 2026 EPS forecast but stock slips - Investing.com UK
Earnings call transcript: Inovio beats Q1 2026 EPS forecast but stock slips By Investing.com - Investing.com South Africa
Inovio Stock Price Today | NASDAQ: INO Live - Investing.com
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio (NASDAQ: INO) CEO nets shares from RSU vesting and tax withholding - Stock Titan
Inovio Pharmaceuticals (INO) CFO exercises 4,771 RSUs and has 2,571 shares withheld for taxes - Stock Titan
INOVIO (NASDAQ: INO) CSO settles RSUs, shares withheld for tax - Stock Titan
INOVIO (NASDAQ: INO) CMO vests RSUs and withholds shares for taxes - Stock Titan
Inovio Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:INO) 2026-05-16 - Seeking Alpha
INO Should I Buy - Intellectia AI
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2026 Earnings Call Transcript - Insider Monkey
Highbridge reports 6.19M warrant‑issued shares in Inovio (INO) - Stock Titan
Investigation Alert: Investors who hold shares of Inovio - openPR.com
INOVIO Shares Drop 10% After Discounted $25 Million Public Offering - MSN
Inovio Pharmaceuticals stock (US45773H2013): Q1 2026 results and INO-3107 FDA review - AD HOC NEWS
Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms (NASDAQ:INO) - Seeking Alpha
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
INOVIO Reports First Quarter 2026 Financial Results and Recent B - GuruFocus
Inovio Pharmaceuticals Inc (INO) Q1 2026 Earnings Call Highlights: Progress and Challenges in Advancing INO-3107 - GuruFocus
Inovio outlines cash runway into Q1 2027 as INO-3107 targets October 30, 2026 PDUFA date - MSN
Inovio and Fossil Q1 results highlight strategic progress - MSN
Salt Lake City Topic INOVIO PHARMACEUTICALS, INC. | News, Weather, Sports, Breaking News - KMYU
Earnings call transcript: Inovio’s Q1 2026 highlights clinical progress, stock rises 2.84% - Investing.com UK
Inovio Pharmaceuticals (INO) Q1 2026 Earnings Report Highlights Progress and Cash Position - GuruFocus
Is Inovio Pharmaceuticals (INO) Still 545.2% Overvalued After Q1 - GuruFocus
Inovio (INO) Q1 2026 Earnings Call Transcript - AOL.com
Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call - Benzinga
Inovio Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Inovio’s Q1 2026 highlights clinical progress, stock rises 2.84% By Investing.com - Investing.com South Africa
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.72%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):